Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host diseaseThe FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation Share XShock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host diseasehttps://pharmaphorum.com/news/fda-issues-shock-rejection-for-mesoblasts-ryoncil-in-graft-versus-host-disease/
FDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomaBristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy has been approved in the US in a new indication Share XFDA approves BMS’ Opdivo and Yervoy combination in first-line mesotheliomahttps://pharmaphorum.com/news/fda-approves-bms-opdivo-and-yervoy-combination-in-first-line-mesothelioma/
Roche pays $200m for Vaccibody’s cancer vaccine drugRoche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which Share XRoche pays $200m for Vaccibody’s cancer vaccine drughttps://pharmaphorum.com/news/roche-pays-200m-for-vaccibodys/
CTI wins over FDA to claim early review of myelofibrosis drugShares in US biotech CTI BioPharma have shot up after the FDA agreed to an accelerated review early Share XCTI wins over FDA to claim early review of myelofibrosis drughttps://pharmaphorum.com/news/cti-wins-over-fda-to-claim-early-review-of-myelofibrosis-drug/
Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in ChinaPfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration Share XPfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in Chinahttps://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/
Blank cheque company merger creates cancer specialist VinceraLifeSci Acquisition – a so-called ‘blank cheque’ company – has announced a $60 million merger with Vincera Pharma Share XBlank cheque company merger creates cancer specialist Vincerahttps://pharmaphorum.com/news/blank-cheque-company-merger-creates-cancer-specialist-vincera/
Junshi plans filings after toripalimab hits target in upper throat cancerChina’s Junshi Biosciences has said it plans filings for a new cancer immunotherapy after its toripalimab outperformed standard Share XJunshi plans filings after toripalimab hits target in upper throat cancerhttps://pharmaphorum.com/news/junshi-plans-filings-after-toripalimab-hits-target-in-upper-throat-cancer/
Valirx eyes partnerships as first VAL201 study hits the markShares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of Share XValirx eyes partnerships as first VAL201 study hits the markhttps://pharmaphorum.com/news/valirx-eyes-partnerships-as-first-val201-study-hits-the-mark/
FDA fast-tracks Leap’s gastric cancer immunotherapyLeap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric Share XFDA fast-tracks Leap’s gastric cancer immunotherapyhttps://pharmaphorum.com/news/fda-fast-tracks-leaps-gastric-cancer-immunotherapy/
New data reinforce Keytruda’s dominance in first-line lung cancerFive-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off Share XNew data reinforce Keytruda’s dominance in first-line lung cancerhttps://pharmaphorum.com/news/new-data-reinforce-keytrudas-dominance-in-first-line-lung-cancer/
FDA’s review date for BMS’ ide-cel sneaks under the CVR wireThe FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, Share XFDA’s review date for BMS’ ide-cel sneaks under the CVR wirehttps://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/
Amgen offers hope in KRAS-mutated cancer with sotorasib read-outLast year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug Share XAmgen offers hope in KRAS-mutated cancer with sotorasib read-outhttps://pharmaphorum.com/news/amgen-offers-hope-in-kras/
EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancerAstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s Share XEU regulators back uses for AZ’s Lynparza in prostate and ovarian cancerhttps://pharmaphorum.com/news/az-grabs-twin-eu-approval-for-lynparza-in-prostate-and-ovarian-cancer-uses/
